<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00194792</url>
  </required_header>
  <id_info>
    <org_study_id>6277</org_study_id>
    <secondary_id>NCI-2010-00549</secondary_id>
    <nct_id>NCT00194792</nct_id>
  </id_info>
  <brief_title>Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer</brief_title>
  <official_title>Neoadjuvant Complete Hormonal Blockade Followed by Neoadjuvant Chemotherapy for Resectable Hormone Receptor Positive, HER-2/Neu Negative Breast Cancer, A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well giving hormone therapy together with combination
      chemotherapy before and after surgery works in treating patients with stage I-IIIA breast
      cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using
      exemestane and triptorelin pamoate may fight breast cancer by lowering the amount of estrogen
      the body makes. Drugs used in chemotherapy, such as capecitabine, methotrexate, vinorelbine
      ditartrate, and paclitaxel, work in different ways to stop the growth of tumor cells, either
      by killing the cells or by stopping them from dividing. Giving hormone therapy together with
      combination chemotherapy before surgery may make the tumor smaller and reduce the amount of
      normal tissue that needs to be removed. Giving these treatments after surgery may kill any
      tumor cells that remain after surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the pathologic response rate in patients with operable breast cancer treated
      with a two part, neoadjuvant regimen consisting of complete hormonal blockade (CHB) for 2
      weeks followed by four three-week cycles of Xeloda, Methotrexate and Navelbine with
      continuation of complete hormonal blockade.

      SECONDARY OBJECTIVES:

      I. To assess the clinical response rate in patients with surgically resectable breast cancer
      treated with complete hormonal blockade and four three-week cycles of Xeloda, Methotrexate
      and Navelbine.

      II. To assess the toxicity associated with these regimens. III. To assess the relapse rate,
      overall and disease-free survival in patients with operable breast cancer when treated with
      neoadjuvant CHB and XMN + CHB followed by adjuvant treatment using XMN or Taxol.

      IV. To assess whether the phenotype of breast cancer changes with treatment. V. To assess
      whether phenotypic changes in breast tumors predict outcome.

      OUTLINE:

      NEOADJUVANT CHB: Patients receive exemestane orally (PO) daily for 14 weeks. Premenopausal
      patients also receive triptorelin pamoate intramuscularly (IM) once monthly for 4 months
      beginning 2 weeks before the initiation of exemestane.

      NEOADJUVANT CHEMOTHERAPY: Patients receive capecitabine PO twice daily (BID) on days 1-14 and
      methotrexate intravenously (IV) and vinorelbine ditartrate IV over 6-10 minutes on days 1, 8,
      and 15. Treatment repeats every 21 days for 4 courses.

      SURGERY: Patients then undergo definitive surgical resection with or without radiation
      therapy.

      ADJUVANT CHEMOTHERAPY: Patients with microscopic complete response (pCR) or disease that has
      been down-staged to =&lt; 1 cm with no positive nodes receive capecitabine PO BID on days 1-14
      and methotrexate IV and vinorelbine ditartrate IV over 6-10 minutes on days 1, 8, and 15.
      Treatment repeats every 21 days for 4 courses. Patients with down-staged T and 0 or 1
      positive node receive paclitaxel IV over 1 hour once weekly for 12 weeks.

      ADJUVANT HORMONAL THERAPY: Patients receive hormonal therapy for 5 years.

      Treatment continues in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed every 3 months for 3 years, every
      6 months for 2 years, and then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinical Response</measure>
    <time_frame>1 month</time_frame>
    <description>Defined as a &gt; 50% decrease in sum of the products of the perpendicular diameters of bidimensionally measurable disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Microscopic Pathologic Complete Response and Macroscopic Pathologic Complete Response</measure>
    <time_frame>From date of treatment start to surgery</time_frame>
    <description>Defined as no evidence of microscopic invasive tumor at the primary site or in the regional lymph nodes at the time of definitive surgical resection and the examining pathologist cannot identify gross residual tumor mass in the surgical specimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Kaplan-Meier estimate assessed at 5 years</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>From the start of protocol therapy until the date of death from any cause or the last date the patient was known to be alive. Kaplan-Meier estimate assessed at 5 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of All Grade 2, 3, 4 Adverse Events or Fatal Toxicities</measure>
    <time_frame>Monthly during neoadjuvant treatment and then 6 months following treatment (including surgery)</time_frame>
    <description>Count of all incidences of grade 2, 3, 4 adverse events and fatal toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Dose Reduction, Treatment Interruption, or Treatment Discontinuation</measure>
    <time_frame>During adjuvant and neoadjuvant chemotherapy</time_frame>
    <description>Count of patients with dose reduction, treatment interruption, or treatment discontinuation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of Molecular Markers With Response, Time to Progression, and Survival</measure>
    <time_frame>Weekly during CHB and XMN and pacitaxel</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Estrogen Receptor-positive Breast Cancer</condition>
  <condition>HER2-negative Breast Cancer</condition>
  <condition>Progesterone Receptor-positive Breast Cancer</condition>
  <condition>Stage I Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (hormone therapy and chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (hormone therapy and chemotherapy)</arm_group_label>
    <other_name>Aromasin</other_name>
    <other_name>FCE-24304</other_name>
    <other_name>PNU 155971</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triptorelin pamoate</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Treatment (hormone therapy and chemotherapy)</arm_group_label>
    <other_name>Pamorelin</other_name>
    <other_name>Trelstar Depot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (hormone therapy and chemotherapy)</arm_group_label>
    <other_name>CAPE</other_name>
    <other_name>Ro 09-1978/000</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (hormone therapy and chemotherapy)</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine tartrate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (hormone therapy and chemotherapy)</arm_group_label>
    <other_name>Eunades</other_name>
    <other_name>navelbine ditartrate</other_name>
    <other_name>NVB</other_name>
    <other_name>VNB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (hormone therapy and chemotherapy)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo lumpectomy or mastectomy</description>
    <arm_group_label>Treatment (hormone therapy and chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Treatment (hormone therapy and chemotherapy)</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (hormone therapy and chemotherapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have histologically confirmed, operable ER or PR +, HER2/neu negative,
             radiographically measurable breast cancer &gt; 1cm (Operable lesions are T1c - T3 and N0
             - N2a; histologic confirmation should be by core needle biopsy only)

          -  Be chemotherapy naive

          -  Have an ECOG performance status of =&lt; 2

          -  Be assessed for menopausal status (For study purposes, postmenopausal is defined as: a
             prior documented bilateral oophorectomy, or a history of at least 12 months without
             spontaneous menstrual bleeding, or age 60 or older with a prior hysterectomy without
             oophorectomy, or Age less than 60 with a prior hysterectomy without oophorectomy [or
             in whom the status of the ovaries is unknown], with a documented FSH level
             demonstrating confirmatory elevation in the postmenopausal range for the lab)

          -  All premenopausal patients must have a baseline FSH and LH

          -  ANC &gt;= 1,500

          -  Platelet count &gt;= 100,000

          -  Serum creatinine =&lt; 1.5 x IULN

          -  Estimated creatinine clearance &gt; 50 ml/min

          -  Have staging studies and tumor assessment prior to registration

          -  Bone density exam must be done within the first 3 months of complete hormonal blockade

          -  Have a negative pregnancy test within seven days prior to registration if of
             childbearing potential

          -  Be informed of the investigational nature of this study and provide written informed
             consent in accordance with institutional and federal guidelines prior to study
             specific screening procedures

        Exclusion Criteria:

          -  Primary tumor =&lt; 1 cm, not measurable; inflammatory disease

          -  Pregnant or lactating; women of childbearing potential with either a positive or no
             pregnancy test at baseline are excluded (Women of childbearing potential who are not
             using a reliable and appropriate contraceptive method are excluded; patients must
             agree to continue contraception for 30 days from the last study drug administration)

          -  Prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity
             to 5-fluorouracil

          -  Previous enrollment in an investigational drug study within the last 4 weeks

          -  Evidence of distant metastatic disease

          -  Prior chemotherapy or hormonal therapy for breast cancer

          -  Prior malignancy other than adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer, other stage I or II cancer from which the patient has
             been disease free for at least 5 years

          -  History of uncontrolled seizures, central nervous system disorders, or psychiatric
             disability judged by the investigator to be clinically significant, precluding
             informed consent, or interfering with compliance with oral drug intake

          -  Any other life-threatening illness (e.g. serious, uncontrolled concurrent infection or
             clinically significant cardiac disease - congestive heart failure, symptomatic
             coronary artery disease, cardiac arrhythmia not well controlled with medication or
             myocardial infarction

          -  Major surgery within four weeks of the start of study treatment without complete
             recovery

          -  Lack of physical integrity of the upper gastrointestinal tract or malabsorption
             syndrome

          -  Known, existing uncontrolled coagulopathy

          -  Unwillingness to give informed consent

          -  Unwillingness to participate or inability to comply with the protocol for the duration
             of the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hannah Linden</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <results_first_submitted>April 14, 2017</results_first_submitted>
  <results_first_submitted_qc>June 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 6, 2017</results_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Hannah Linden</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Hormone Therapy and Chemotherapy)</title>
          <description>See detailed description
exemestane: Given PO
triptorelin pamoate: Given IM
capecitabine: Given PO
methotrexate: Given IV
vinorelbine tartrate: Given IV
paclitaxel: Given IV
therapeutic conventional surgery: Undergo lumpectomy or mastectomy
radiation therapy: Undergo radiation therapy
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Hormone Therapy and Chemotherapy)</title>
          <description>See detailed description
exemestane: Given PO
triptorelin pamoate: Given IM
capecitabine: Given PO
methotrexate: Given IV
vinorelbine tartrate: Given IV
paclitaxel: Given IV
therapeutic conventional surgery: Undergo lumpectomy or mastectomy
radiation therapy: Undergo radiation therapy
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="35" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Response</title>
        <description>Defined as a &gt; 50% decrease in sum of the products of the perpendicular diameters of bidimensionally measurable disease.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Hormone Therapy and Chemotherapy)</title>
            <description>See detailed description
exemestane: Given PO
triptorelin pamoate: Given IM
capecitabine: Given PO
methotrexate: Given IV
vinorelbine tartrate: Given IV
paclitaxel: Given IV
therapeutic conventional surgery: Undergo lumpectomy or mastectomy
radiation therapy: Undergo radiation therapy
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Response</title>
          <description>Defined as a &gt; 50% decrease in sum of the products of the perpendicular diameters of bidimensionally measurable disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Microscopic Pathologic Complete Response and Macroscopic Pathologic Complete Response</title>
        <description>Defined as no evidence of microscopic invasive tumor at the primary site or in the regional lymph nodes at the time of definitive surgical resection and the examining pathologist cannot identify gross residual tumor mass in the surgical specimen.</description>
        <time_frame>From date of treatment start to surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Hormone Therapy and Chemotherapy)</title>
            <description>See detailed description
exemestane: Given PO
triptorelin pamoate: Given IM
capecitabine: Given PO
methotrexate: Given IV
vinorelbine tartrate: Given IV
paclitaxel: Given IV
therapeutic conventional surgery: Undergo lumpectomy or mastectomy
radiation therapy: Undergo radiation therapy
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Microscopic Pathologic Complete Response and Macroscopic Pathologic Complete Response</title>
          <description>Defined as no evidence of microscopic invasive tumor at the primary site or in the regional lymph nodes at the time of definitive surgical resection and the examining pathologist cannot identify gross residual tumor mass in the surgical specimen.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival</title>
        <description>Kaplan-Meier estimate assessed at 5 years</description>
        <time_frame>Up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Hormone Therapy and Chemotherapy)</title>
            <description>See detailed description
exemestane: Given PO
triptorelin pamoate: Given IM
capecitabine: Given PO
methotrexate: Given IV
vinorelbine tartrate: Given IV
paclitaxel: Given IV
therapeutic conventional surgery: Undergo lumpectomy or mastectomy
radiation therapy: Undergo radiation therapy
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>Kaplan-Meier estimate assessed at 5 years</description>
          <units>disease free survival probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" lower_limit="0.61" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>From the start of protocol therapy until the date of death from any cause or the last date the patient was known to be alive. Kaplan-Meier estimate assessed at 5 years.</description>
        <time_frame>Up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Hormone Therapy and Chemotherapy)</title>
            <description>See detailed description
exemestane: Given PO
triptorelin pamoate: Given IM
capecitabine: Given PO
methotrexate: Given IV
vinorelbine tartrate: Given IV
paclitaxel: Given IV
therapeutic conventional surgery: Undergo lumpectomy or mastectomy
radiation therapy: Undergo radiation therapy
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>From the start of protocol therapy until the date of death from any cause or the last date the patient was known to be alive. Kaplan-Meier estimate assessed at 5 years.</description>
          <units>survival probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.76" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Quantification of All Grade 2, 3, 4 Adverse Events or Fatal Toxicities</title>
        <description>Count of all incidences of grade 2, 3, 4 adverse events and fatal toxicities</description>
        <time_frame>Monthly during neoadjuvant treatment and then 6 months following treatment (including surgery)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Hormone Therapy and Chemotherapy)</title>
            <description>See detailed description
exemestane: Given PO
triptorelin pamoate: Given IM
capecitabine: Given PO
methotrexate: Given IV
vinorelbine tartrate: Given IV
paclitaxel: Given IV
therapeutic conventional surgery: Undergo lumpectomy or mastectomy
radiation therapy: Undergo radiation therapy
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Quantification of All Grade 2, 3, 4 Adverse Events or Fatal Toxicities</title>
          <description>Count of all incidences of grade 2, 3, 4 adverse events and fatal toxicities</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose Reduction, Treatment Interruption, or Treatment Discontinuation</title>
        <description>Count of patients with dose reduction, treatment interruption, or treatment discontinuation.</description>
        <time_frame>During adjuvant and neoadjuvant chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Hormone Therapy and Chemotherapy)</title>
            <description>See detailed description
exemestane: Given PO
triptorelin pamoate: Given IM
capecitabine: Given PO
methotrexate: Given IV
vinorelbine tartrate: Given IV
paclitaxel: Given IV
therapeutic conventional surgery: Undergo lumpectomy or mastectomy
radiation therapy: Undergo radiation therapy
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Reduction, Treatment Interruption, or Treatment Discontinuation</title>
          <description>Count of patients with dose reduction, treatment interruption, or treatment discontinuation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adjuvant therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neoadjuvant therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Molecular Markers With Response, Time to Progression, and Survival</title>
        <time_frame>Weekly during CHB and XMN and pacitaxel</time_frame>
        <population>Molecular marker data was not collected for this cohort and thus not possible to report results for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Hormone Therapy and Chemotherapy)</title>
            <description>See detailed description
exemestane: Given PO
triptorelin pamoate: Given IM
capecitabine: Given PO
methotrexate: Given IV
vinorelbine tartrate: Given IV
paclitaxel: Given IV
therapeutic conventional surgery: Undergo lumpectomy or mastectomy
radiation therapy: Undergo radiation therapy
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Molecular Markers With Response, Time to Progression, and Survival</title>
          <population>Molecular marker data was not collected for this cohort and thus not possible to report results for this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Hormone Therapy and Chemotherapy)</title>
          <description>See detailed description
exemestane: Given PO
triptorelin pamoate: Given IM
capecitabine: Given PO
methotrexate: Given IV
vinorelbine tartrate: Given IV
paclitaxel: Given IV
therapeutic conventional surgery: Undergo lumpectomy or mastectomy
radiation therapy: Undergo radiation therapy
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Mucositis (GI)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Mucositis (Oral)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain (abdominal)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>GI Upset/Reflux</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain (arm)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain (neck &amp; jaw)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain (back)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain (subcostal)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Joint Pain/Muscle Aches</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>SGOT Increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>SGPT Increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Albumin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Potassium Decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>White Blood Cells Decreased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hematocrit Decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Sodium Decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Lactate Dehydrogenase Increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Glucose Increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain (bone)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Amenorrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Yeast Infection (vaginal)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Common Cold</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>SOB with activity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dry Skin (hands)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hand Foot Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rash (Eczema)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation (lymphs)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>High Blood Pressure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hot Flashes/Night Sweats</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hannah Linden</name_or_title>
      <organization>University of Washington / Seattle Cancer Care Alliance</organization>
      <phone>206-288-6989</phone>
      <email>hmlinden@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

